Pulmonary hypertension Circulatory System Primary pulmonary hypertension
Conditions
Interventions
Subjects were randomized in a 1:2:2 ratio to receive a single dose of either placebo, niacin 100 mg or niacin 500 mg, respectively. TR jet velocities were measured immediately before, and one-hour pos
Sponsors
Georgetown University Institutional Review Board
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Over the age of 18 2. Display a tricuspid regurgitation jet velocity over 2.7 m/s on an inpatient echocardiogram during their current hospital stay
Exclusion criteria
Exclusion criteria: 1. Inability to provide written informed consent 2. Known pulmonary vascular disease 3. Known intolerance to niacin or current treatment with niacin 4. Current treatment with a non-steroidal anti-inflammatory drug (NSAID) 5. Known liver disease (AST/ALT > 3x the upper limit of normal) 6. Patients currently on ventilator support or using a bi-level positive airway pressure (BiPAP) device
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean tricuspid regurgitation jet velocity measured in meters/second one hour after study drug administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in maximum tricuspid regurgitation jet velocity measured in meters/second one hour after study drug administration. | — |
Countries
United States of America
Contacts
Public ContactMartin McNamara
Outcome results
None listed